- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03856047
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
July 17, 2023 updated by: Novo Nordisk A/S
Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.
Participants will either take NNC0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance.
Participants will need to take one injection once a week or once a day, depending on the treatment.
The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.
The study will last for about 8 months.
Participants will have 12 clinic visits with the study doctor.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
706
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2T 5C7
- Novo Nordisk Investigational Site
-
Calgary, Alberta, Canada, T2V 4J2
- Novo Nordisk Investigational Site
-
Edmonton, Alberta, Canada, T6H 2L4
- Novo Nordisk Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G8
- Novo Nordisk Investigational Site
-
Hamilton, Ontario, Canada, L8M 1K7
- Novo Nordisk Investigational Site
-
-
-
-
-
Aarhus N, Denmark, 8200
- Novo Nordisk Investigational Site
-
Hvidovre, Denmark, 2650
- Novo Nordisk Investigational Site
-
-
-
-
-
Jyväskylä, Finland, 40620
- Novo Nordisk Investigational Site
-
Kuopio, Finland, 70211
- Novo Nordisk Investigational Site
-
Turku, Finland, 20520
- Novo Nordisk Investigational Site
-
University Of Helsinki, Finland, 00014
- Novo Nordisk Investigational Site
-
-
-
-
-
Dublin, Ireland, DUBLIN 4
- Novo Nordisk Investigational Site
-
-
-
-
-
Tokyo, Japan, 103-0027
- Novo Nordisk Investigational Site
-
Tokyo, Japan, 103-0028
- Novo Nordisk Investigational Site
-
Tokyo, Japan, 160-0008
- Novo Nordisk Investigational Site
-
-
-
-
-
Bialystok, Poland, 15-281
- Novo Nordisk Investigational Site
-
Katowice, Poland, 40-001
- Novo Nordisk Investigational Site
-
Poznan, Poland, 60-589
- Novo Nordisk Investigational Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Novo Nordisk Investigational Site
-
Novi Sad, Serbia, 21000
- Novo Nordisk Investigational Site
-
-
-
-
Free State
-
Bloemfontein, Free State, South Africa, 9300
- Novo Nordisk Investigational Site
-
-
Gauteng
-
Boksburg, Gauteng, South Africa, 1466
- Novo Nordisk Investigational Site
-
Johannesburg, Gauteng, South Africa, 1812
- Novo Nordisk Investigational Site
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, South Africa, 4091
- Novo Nordisk Investigational Site
-
Durban, KwaZulu-Natal, South Africa, 4450
- Novo Nordisk Investigational Site
-
-
-
-
-
Bradford-on-Avon, United Kingdom, BA15 1DQ
- Novo Nordisk Investigational Site
-
Bristol, United Kingdom, BS10 5NB
- Novo Nordisk Investigational Site
-
Coventry, United Kingdom, CV2 2DX
- Novo Nordisk Investigational Site
-
Liverpool, United Kingdom, L9 7AL
- Novo Nordisk Investigational Site
-
London, United Kingdom, SE1 9RT
- Novo Nordisk Investigational Site
-
London, United Kingdom, WC1E 6JF
- Novo Nordisk Investigational Site
-
Rotherham, United Kingdom, S65 1DA
- Novo Nordisk Investigational Site
-
-
-
-
California
-
Anaheim, California, United States, 92801
- Novo Nordisk Investigational Site
-
Spring Valley, California, United States, 91978
- Novo Nordisk Investigational Site
-
-
Florida
-
Crystal River, Florida, United States, 34429
- Novo Nordisk Investigational Site
-
Jacksonville, Florida, United States, 32216
- Novo Nordisk Investigational Site
-
Pembroke Pines, Florida, United States, 33027
- Novo Nordisk Investigational Site
-
Ponte Vedra, Florida, United States, 32081
- Novo Nordisk Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Novo Nordisk Investigational Site
-
-
Maryland
-
Elkridge, Maryland, United States, 21075-6437
- Novo Nordisk Investigational Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Novo Nordisk Investigational Site
-
-
New York
-
Rochester, New York, United States, 14609
- Novo Nordisk Investigational Site
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27408
- Novo Nordisk Investigational Site
-
-
Ohio
-
Franklin, Ohio, United States, 45005
- Novo Nordisk Investigational Site
-
Mason, Ohio, United States, 45040-6815
- Novo Nordisk Investigational Site
-
Wadsworth, Ohio, United States, 44281
- Novo Nordisk Investigational Site
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
- Novo Nordisk Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Novo Nordisk Investigational Site
-
Gaffney, South Carolina, United States, 29341
- Novo Nordisk Investigational Site
-
Spartanburg, South Carolina, United States, 29303
- Novo Nordisk Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620-7352
- Novo Nordisk Investigational Site
-
-
Texas
-
Round Rock, Texas, United States, 78681
- Novo Nordisk Investigational Site
-
-
Virginia
-
Arlington, Virginia, United States, 22206
- Novo Nordisk Investigational Site
-
Richmond, Virginia, United States, 23294
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18 years or older at the time of signing the informed consent.
- Female subject of non-childbearing potential or Male subject who is surgically sterilised (vasectomy) or who is willing to use adequate contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial').
- BMI equal to 30.0 kg/m^2 or greater or BMI equal to 27.0 kg/m^2 or greater with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension or dyslipidaemia (to be assessed at the investigator's discretion).
Exclusion Criteria:
- HbA1c equal to 48 mmol/mol (6.5 percentage) or greater as measured by the central laboratory at screening.
- A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior to screening irrespective of medical records.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NNC0174-0833, 4.5 mg
Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
|
Participants will get one dose of NNC0174-0833 once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Experimental: NNC0174-0833, 2.4 mg
Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
|
Participants will get one dose of NNC0174-0833 once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Experimental: NNC0174-0833, 1.2 mg
Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
|
Participants will get one dose of NNC0174-0833 once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Experimental: NNC0174-0833, 0.6 mg
Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
|
Participants will get one dose of NNC0174-0833 once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Experimental: NNC0174-0833 0.3 mg
Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
|
Participants will get one dose of NNC0174-0833 once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Placebo Comparator: Placebo 2.4 mg (NNC0174-0833)
Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
|
Participants will get one dose of Placebo (NNC0174-0833) once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Placebo Comparator: Placebo 4.5 mg (NNC0174-0833)
Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
|
Participants will get one dose of Placebo (NNC0174-0833) once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Placebo Comparator: Placebo 1.2 mg (NNC0174-0833)
Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
|
Participants will get one dose of Placebo (NNC0174-0833) once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Placebo Comparator: Placebo 0.6 mg (NNC0174-0833)
Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
|
Participants will get one dose of Placebo (NNC0174-0833) once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Placebo Comparator: Placebo 0.3 mg (NNC0174-0833)
Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
|
Participants will get one dose of Placebo (NNC0174-0833) once weekly.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
|
Active Comparator: Liraglutide 3.0 mg
Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
|
Participants will get one dose of liraglutide 3.0 mg once daily.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector.
Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily.
The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
|
Placebo Comparator: Placebo 3.0 mg (Liraglutide)
Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
|
Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily.
The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector.
Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg.
The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Weight (%)
Time Frame: From baseline (week 0) to week 26
|
Change in body weight (%) from week 0 to week 26 is presented.
For descriptive analysis and statistical analysis the endpoint was evaluated based on the data from in-trial period and treatment adherent period, respectively.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
Treatment-adherent: a participant is treatment adherent until the first time of non-adherence defined as: participant has not been dosed with trial product within the prior 14 days; participant has received other weight management drug or bariatric surgery; participant has not reached target dose at a pre-specified week; After the pre-specified evaluation week for the target dose, the participant has not received the target dose ±10% within the prior 14 days.
|
From baseline (week 0) to week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Weight Loss of ≥ 5% of Baseline Body Weight at 26 Weeks
Time Frame: Week 26
|
Percentage of participants who achieved a weight loss of greater than or equal to (≥) 5% of baseline (week 0) body weight at 26 weeks is presented.
The numbers presented are predictions from a logistic regression model.
|
Week 26
|
Percentage of Participants With Weight Loss of ≥ 10% of Baseline Body Weight at 26 Weeks
Time Frame: Week 26
|
Percentage of participants who achieved a weight loss ≥ 10% of baseline (week 0) body weight at 26 weeks is presented.
The numbers presented are predictions from a logistic regression model.
|
Week 26
|
Change in Body Weight (Kg)
Time Frame: From baseline (week 0) to week 26
|
Change in body weight (Kg) from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Waist Circumference
Time Frame: From baseline (week 0) to week 26
|
Change in waist circumference from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Total Cholesterol
Time Frame: From baseline (week 0) to week 26
|
Change in total cholesterol from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in High Density Lipoprotein (HDL) Cholesterol
Time Frame: From baseline (week 0) to week 26
|
Change in HDL cholesterol from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Low Density Lipoprotein (LDL) Cholesterol
Time Frame: From baseline (week 0) to week 26
|
Change in LDL cholesterol from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Very Low Density Lipoprotein (VLDL) Cholesterol
Time Frame: From baseline (week 0) to week 26
|
Change in VLDL cholesterol from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Triglycerides
Time Frame: From baseline (week 0) to week 26
|
Change in triglycerides from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Glycosylated Haemoglobin (HbA1c) (%-Point)
Time Frame: From baseline (week 0) to week 26
|
Change in HbA1c (measured as percentage point of HbA1c) from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in HbA1c (mmol/Mol)
Time Frame: From baseline (week 0) to week 26
|
Change in HbA1c (measured as millimoles per mole (mmol/mol)) from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Fasting Plasma Glucose (FPG) (mmol/L)
Time Frame: From baseline (week 0) to week 26
|
Change in FPG (measured as mmol/L)) from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in FPG (mg/dL)
Time Frame: From baseline (week 0) to week 26
|
Change in FPG (measured as milligrams per decilitre (mg/dL)) from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Change in Fasting Insulin
Time Frame: From baseline (week 0) to week 26
|
In the below table, fasting insulin data at week 0 and at week 26 is presented.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Percentage Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Time Frame: From baseline (week 0) to week 26
|
Percentage change in HOMA-IR from week 0 to week 26 is presented.
Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body.
HOMA-IR is calculated using a subject's fasting plasma insulin and glucose levels.
HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5.
HOMA-IR scores are classified as follows: less than 1.0: considered Insulin sensitive, 0.5-1.4:
considered Healthy, Above 1.8: considered Early insulin resistance; Above 2.7 is considered significant insulin resistance.
HOMA-IR score ranges from 0-infinity (no upper limit).
Higher the score, higher the level of insulin resistance.
Endpoint was evaluated based on data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in in-trial period.
|
From baseline (week 0) to week 26
|
Change in Homeostatic Model Assessment of Beta-cell Function (HOMA-beta)
Time Frame: From baseline (week 0) to week 26
|
Change between the value of HOMA-beta cell function collected at Week 26 and HOMA-beta cell function collected at Week 0 is presented.
The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B).
HOMA %B = 20 * insulin (micro international units per milliliter (µIU/mL)) / fasting plasma glucose (millimoles per liter (mmol/L)) - 3.5.
HOMA-beta score ranges from minus infinity to infinity (no limits).
The higher the score the better beta-cell function for HOMA-beta.
The endpoint was evaluated based on the data from in-trial period.
In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
|
From baseline (week 0) to week 26
|
Number of Treatment-emergent Adverse Events (TEAEs)
Time Frame: From week 0 to week 32
|
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or used a medicinal product, whether or not considered related to the medicinal product or usage.
All AEs reported here are TEAEs.
TEAE is defined as an event that had onset date during the on-treatment period.
The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
|
From week 0 to week 32
|
Number of Treatment-emergent Serious Adverse Events (TESAEs)
Time Frame: From week 0 to week 32
|
An AE was any untoward medical occurrence in a clinical trial participant administered or used a medicinal product, whether or not considered related to the medicinal product or usage.
Serious AE is an AE that resulted in death, life threatening, persistent or significant incapacity or substantial disruption of ability to conduct normal life functions, hospitalization or prolongation of existing hospitalization, congenital anomaly or birth defect, important medical events that may not result in death, be life threatening, or require hospitalization.
All SAEs reported in the below table are TESAEs.
The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
|
From week 0 to week 32
|
Number of Participants With Occurrence of Anti-drug Antibodies Towards Cagrilintide
Time Frame: From week 0 to week 32
|
Number of participants with occurrence of anti-drug antibodies towards cagrilintide from randomisation from week 0 to week 32 is presented.
The endpoint was evaluated based on the data from in-trial period.
The in-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site.
Follow-up time for positive antibodies was not included in the in-trial period.
This endpoint is applicable only for the cagrilintide treatment arms.
|
From week 0 to week 32
|
Change in Diastolic Blood Pressure (DBP)
Time Frame: From baseline (week 0) to week 26
|
Blood pressure was measured in a sitting position after 5 minutes of rest.
The end point is evaluated while the subject is treatment-adherent.
A participant is treatment adherent until the first time of non-adherence defined as: a) the participant has not been dosed with trial product within the prior 14 days; b) the participant has received other weight management drug or bariatric surgery c) the participant has not reached target dose at a pre-specified week d) After the pre-specified evaluation week for the target dose, the participant has not received the target dose +/- 10 % within the prior 14 days.
This endpoint is applicable only for the cagrilintide treatment arms.
|
From baseline (week 0) to week 26
|
Change in Systolic Blood Pressure (SBP)
Time Frame: From baseline (week 0) to week 26
|
Blood pressure was measured in a sitting position after 5 minutes of rest.
The end point is evaluated while the subject is treatment-adherent.
A participant is treatment adherent until the first time of non-adherence defined as: a) the participant has not been dosed with trial product within the prior 14 days; b) the participant has received other weight management drug or bariatric surgery c) the participant has not reached target dose at a pre-specified week d) After the pre-specified evaluation week for the target dose, the participant has not received the target dose +/- 10 % within the prior 14 days.
This endpoint is applicable only for the cagrilintide treatment arms.
|
From baseline (week 0) to week 26
|
Change in Pulse
Time Frame: From baseline (week 0) to week 26
|
Change in pulse from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
|
From baseline (week 0) to week 26
|
Change in High Sensitivity C-reactive Protein (hsCRP)
Time Frame: From baseline (week 0) to week 26
|
In the below table, hsCRP data at week 0 and at week 26 is presented.
The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
|
From baseline (week 0) to week 26
|
Change in Plasminogen Activator Inhibitor-1 (PAI-1) Activity
Time Frame: From baseline (week 0) to week 26
|
Due to the assay development issue faced by the laboratory, the Plasminogen Activator Inhibitor-1 (PAI-1) activity (mg/L) was not performed in the study.
|
From baseline (week 0) to week 26
|
Change in Renin Activity
Time Frame: From baseline (week 0) to week 26
|
Change in renin activity from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
|
From baseline (week 0) to week 26
|
Change in Aldosterone
Time Frame: From baseline (week 0) to week 26
|
Change in aldosterone from week 0 to week 26 is presented.
The endpoint was evaluated based on the data from on-treatment period which started from the date of first trial product administration to date of last trial product administration excluding potential off-treatment time intervals triggered by at least 6 consecutive missed doses for cagrilintide or 6 consecutive weeks of missed dosing with liraglutide.
|
From baseline (week 0) to week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2019
Primary Completion (Actual)
March 2, 2020
Study Completion (Actual)
March 25, 2021
Study Registration Dates
First Submitted
February 25, 2019
First Submitted That Met QC Criteria
February 25, 2019
First Posted (Actual)
February 27, 2019
Study Record Updates
Last Update Posted (Actual)
July 18, 2023
Last Update Submitted That Met QC Criteria
July 17, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9838-4433
- U1111-1214-0429 (Other Identifier: World Health Organization (WHO))
- 2018-001945-14 (Registry Identifier: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on NNC0174-0833
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SCompletedOverweight and ObesityChina
-
Novo Nordisk A/SCompletedObesity | Metabolism and Nutrition DisorderUnited States
-
Novo Nordisk A/SCompletedObesity | Metabolism and Nutrition DisorderUnited States
-
Novo Nordisk A/SRecruiting
-
Novo Nordisk A/SActive, not recruitingNon-alcoholic SteatohepatitisSpain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
-
Novo Nordisk A/SCompleted
-
Josep Rodes-CabauiVascularCompletedCoronary Heart DiseaseSpain